FIG 1.
(A) Carbohydrate antigen 19-9 (CA19-9) at baseline, in response to chemotherapy, and then in response to crizotinib. (B) Target lesion measurements before and after crizotinib treatment. ULN, upper limit of normal (36.0 U/mL).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.